Jounce Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results - Completed upsized initial public offering raising $117.1 million in gross proceeds -  - Continue to advance lead product candidate JTX-2011 through Phase 1/2 ICONIC trial and to broaden new...

Jounce Therapeutics to Present at Cowen and Company 37th Annual Health Care Conference CAMBRIDGE, Mass., Feb. 28, 2017 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical stage company focused on the discovery and development of novel cancer immunotherapies and...